Immunovant’s (IMVT) Overweight Rating Reiterated at Cantor Fitzgerald
Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a note issued to investors on Friday, PriceTargets.com reports. A number of other equities analysts have also recently commented on IMVT. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Immunovant in a research note on […]
More Stories
Analysts Set Life360, Inc. (NASDAQ:LIF) PT at $44.75
Life360, Inc. (NASDAQ:LIF – Get Free Report) has been assigned a consensus rating of “Buy” from the eight research firms...
Aemetis, Inc. (NASDAQ:AMTX) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of Aemetis, Inc. (NASDAQ:AMTX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the...
StockNews.com Downgrades Brightcove (NASDAQ:BCOV) to Buy
StockNews.com cut shares of Brightcove (NASDAQ:BCOV – Free Report) from a strong-buy rating to a buy rating in a research...
StockNews.com Upgrades Team (NYSE:TISI) to “Strong-Buy”
StockNews.com upgraded shares of Team (NYSE:TISI – Free Report) from a buy rating to a strong-buy rating in a research...
Chicago Rivet & Machine (NYSEAMERICAN:CVR) Now Covered by Analysts at StockNews.com
StockNews.com began coverage on shares of Chicago Rivet & Machine (NYSEAMERICAN:CVR – Free Report) in a report published on Wednesday...
Aeries Technology (AERT) & Its Competitors Head-To-Head Comparison
Profitability This table compares Aeries Technology and its peers’ net margins, return on equity and return on assets. Net Margins...